Labor and Industry Joint Letter to Becerra, Pelosi, and Schumer
On April 9, 2021, top leaders of unions and companies who are members of PILMA sent letters to Majority Leader Schumer, Secretary Becerra, and House Speaker Pelosi on the importance of biopharmaceutical facilities built by highly-skilled labor, the robust union jobs supported by the industry, and policies that support or upend this important partnership. Read […]
USTR Letter: PILMA Supports Protection of Intellectual Property Rights
On March 1, 2021, General President of SMART and PILMA Chairman Joseph Sellers, Jr. sent the following letter to the Acting U.S. Trade Representative Maria L. Pagan urging continued protections of intellectual property: View letter from President Sellers. View letter from PILMA Executive Director Timothy Dickson. March 1, 2021Maria L. PaganActing United States Trade Representative600 […]
Macomb Daily: Investment in high-tech fields will strengthen state’s economy
February 10, 2021 Authored by Jon DeRoo, financial secretary for UA Local 98, Detroit, MI The COVID-19 pandemic has created uncertainty across industries. The men and women of the Michigan building trades know this intimately. Early on during this crisis, the construction industry was shut down entirely as we looked for ways to deal with […]
The Electrical Worker Online: Labor and the COVID-19 Vaccine
View the article on the IBEW website. View the downloadable article summary. January 2021 Edition One year after the first cases of COVID-19 were diagnosed in North America, vaccines from Pfizer, AstraZeneca and Moderna are on the verge of becoming widely available. And while IBEW members are not the scientists creating those vaccines, they have […]
TribLive: Trump’s reference pricing order imports joblessness
Former Pennsylvania Congressman Ron Klink authored the following op-ed published on TribLive: October 8, 2020 Never in the history of the modern world has there been such a desperate need for the pharmaceutical industry to be able to save our world and return all of us to a form of normality. Covid-19 is impacting everyone, […]
President Sellers Comments on CMS Notice of Proposed Rule Making
SMART General President Joseph Sellers, Jr. submitted the following comment on the CMS NPRM noting the potential negative impact of the rule on patient access. Download the comment here. The Honorable Seema VermaAdministratorCenters for Medicare & Medicaid ServicesU.S. Department of Health and Human Services Attention: CMS–2482-P Re: Establishing Minimum Standards in Medicaid State Drug Utilization […]
PILMA Statement Opposing Price Controls in ACA Stabilization Legislation
On June 24, 2020, PILMA released the following statement in opposition to price controls contained in the ACA Stabilization legislation. Download the statement here. The coronavirus pandemic has elevated the importance of The Pharmaceutical Industry Labor-Management Association (PILMA), a coalition of unions in the building construction trades and companies in the biopharmaceutical industry. During this […]
PILMA Statement on the Importance of Health Insurance Continuity Amid the COVID-19 Pandemic
The PILMA partners adopted the following statement on May 27, 2020: Download the statement here. For 15 years, labor unions in North America’s Building Trades and companies in the biopharmaceutical industry have developed and advanced a partnership, formalized as the Pharmaceutical Industry Labor-Management Association (PILMA). The biopharmaceutical industry is a vital sector in the United […]
PILMA Partners Commit to Fighting COVID-19
Views ways PILMA’s labor and industry partners are committing to fighting COVID-19. View the biopharmaceutical industry’s principles to beat COVID-19. During the COVID-19 pandemic, the long-standing partnership between the biopharmaceutical industry and highly skilled union construction workers has become ever more important. The PILMA partnership’s mission to create quality union construction jobs, foster innovation, and […]
Data shows half of all spending on brand medicines is retained by manufacturer
Last year, PILMA in collaboration with union health care and benefits expert Randy DeFrehn released a report titled “An Understanding and Implications of the Cost Drivers in the Drug Supply Chain.” PILMA combined DeFrehn’s findings with data from a new report by Berkeley Research Group to extrapolate on the original report and provide insight into which entities in the supply chain are receiving an increasing share of revenue from prescription medicines.